Therefore, the inhibition of BCL10 may represent a potentially novel therapeutic method for different CB-SMOC-dependent disease conditions, ranging from ABC-DLBCL and other aggressive cancers to inflammatory diseases such as psoriasis. Here, BCL10 is linked to diffuse large B-cell lymphoma.